Milestone Scientific

Milestone Scientific, Inc. is a biomedical technology research and development company, which patents, designs, and develops diagnostic and therapeutic injection technologies and instruments. It operates through the following segments: Dental, Medical, and Corporate. The Corporate segment refers to executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities, and public company compliance costs. Its solutions include CompuFlo Epidural, CathCheck Verification System, and Single Tooth Anesthesia System. The company was founded on August 17, 1989 and is headquartered in Roseland, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Milestone Scientific reports Q1 revenue, eyes international expansion opportunities

Milestone Scientific's Q1 2024 performance showed revenue over $2.2 million with improved gross margins.
The company's focus on customer relationships and reimbursement strategies is a key strength.
Challenges include revenue decrease and the need for endorsements in the medical space.
Opportunities lie in international expansion, market penetration goals, and increased marketing efforts.

Milestone Scientific reports improved Q2 performance amidst revenue challenges

Milestone Scientific showcased financial improvements in Q2 2024 despite a revenue decrease, with a focus on enhancing operational efficiency and achieving positive cash flow.
The company's strategic partnerships, international expansion plans, and commitment to innovation through intellectual property enhancements signal a path for future growth and market competitiveness.
While facing challenges in revenue generation and operational clarity, Milestone Scientific's strong balance sheet and market positioning offer opportunities for sustained growth and profitability.

Milestone Scientific reports revenue growth and strategic partnerships in Q3

Milestone Scientific shows promising revenue growth and operational improvements in Q3 2024, driven by strong Dental division performance and international sales.
Strategic partnerships and a solid financial position enhance market reach and provide a foundation for future growth.
Challenges include reducing net losses, driving market adoption of CompuFlo, and navigating Medicare coverage expansion, while opportunities exist in reimbursement initiatives and market expansion post-approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ROSELAND, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced it has entered into an agreement with Andau Medical to distribute the STA Single Tooth Anesthesia System ® in the United States and Canada.

Milestone Scientific Names Andau Medical as an Additional Distributor for the STA Single Tooth Anesthesia System® in North America

Milestone Scientific Inc (NYSE:MLSS) said that following a successful trial, it has signed an agreement for the purchase of its CompuFlo Epidural and CathCheck Verification System disposables with a major Northeast teaching hospital. “We are honored to announce the adoption of our CompuFlo Epidural and CathCheck Verification System by yet another important and prestigious hospital,” said Arjan Haverhals, CEO of Milestone Scientific in a statement.

Milestone Scientific announces sale of its CompuFlo Epidural and CathCheck Verification System disposables to a Northeast teaching hospital

ROSELAND, N,J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported, that following a successful trial, it has signed an agreement for the purchase of its CompuFlo® Epidural and CathCheck™ Verification System disposables with a major Northeast teaching hospital, which is part of one of the leading health systems in the United States.

Milestone Scientific Announces Purchase Agreement for its CompuFlo® Epidural / CathCheck™ Verification System Disposables with a Premier Northeast Teaching Hospital

Mr. Haverhals to provide update on growing sales pipeline and goals for 2022 Mr. Haverhals to provide update on growing sales pipeline and goals for 2022

Milestone Scientific CEO Arjan Haverhals to Participate in the Benzinga All Access Event on December 16th

Milestone Scientific Inc (NYSE:MLSS) has announced that Dr Miguel de la Garza, a recognized expert in pain management, has begun incorporating the company's CompuFlo Epidural instrument into his practice for pain management. The move follows approval by Surgery Partners, one of the largest and growing surgical services businesses in the United States, it added.

Milestone Scientific says recognized pain management expert Dr Miguel de la Garza has adopted its CompuFlo Epidural instrument

Marks important step in planned expansion of the CompuFlo Epidural instrument into the pain management market Marks important step in planned expansion of the CompuFlo Epidural instrument into the pain management market

Dr. Miguel de la Garza, President of the Florida Society of Interventional Pain Physicians and Renowned Physician at Surgery Partners, Adopts Milestone Scientific's CompuFlo® Epidural Instrument for Pain Management

Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q3 2021 Results - Earnings Call Transcript

Milestone Scientific, Inc. (MLSS) delivered earnings and revenue surprises of -50.00% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Milestone Scientific, Inc. (MLSS) Reports Q3 Loss, Lags Revenue Estimates

Milestone Scientific Inc (NYSE:MLSS) reported a 69% uplift in revenue in its third quarter to end-September compared to last year, as dental offices began opening up again and the group's medical sales and marketing initiatives began to stick.  For the three months to September 30, the medtech group said revenue was around $2.1 million versus $1.2 million in the year-ago quarter, with dental revenue increasing around $0.8 million on last year.

Milestone Scientific says dental office reopenings and sales and marketing efforts boosted revenue in third quarter

Milestone Scientific (AMEX:MLSS) reported its Q3 earnings results on Monday, November 15, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Milestone Scientific: Q3 Earnings Insights

ROSELAND, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc . (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the third quarter ended September 30, 2021.

Milestone Scientific Reports 69% Increase in Revenue for Third Quarter of 2021

ROSELAND, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, November 15, 2021 to discuss the Company's financial results for the third quarter ended September 30, 2021, as well as the Company's corporate progress and other developments.

Milestone Scientific Schedules Third Quarter 2021 Business Update Conference Call

Milestone Scientific, Inc. (MLSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Milestone Scientific, Inc. (MLSS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

ROSELAND, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Arjan Haverhals, Chief Executive Officer and President of Milestone Scientific, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 at the Wyndham Grand Hotel in Jupiter, Florida.

Milestone Scientific to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Milestone Scientific Inc. (NYSE:MLSS), a developer of computerized drug delivery instruments that provide painless and precise injections, said it has added three new international distributors for the CompuFlo Epidural Instrument, including Andau Medical in Canada, Sanolabor DD in Slovenia, and New Al Farwaniya Surgicals and Medical Equipment LLC in the United Arab Emirates (UAE). “The CompuFlo Epidural Instrument is an important and revolutionary advancement that will significantly improve women's health during one of the most pivotal moments in life, the birth of a child,” Andau Medical CEO Sandi Wright said in a statement.

Milestone Scientific initiates international expansion for its CompuFlo Epidural Instrument

Signs distributors in Canada, Slovenia and United Arab Emirates; expands commercial usage at leading hospital in Germany Signs distributors in Canada, Slovenia and United Arab Emirates; expands commercial usage at leading hospital in Germany

Milestone Scientific Announces International Expansion for their CompuFlo® Epidural Instrument

ROSELAND, NJ / ACCESSWIRE / October 5, 2021 / Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually on October 5 - 8, 2021. Arjan Haverhals, Chief Executive Officer of Milestone Scientific, will present at the conference.

Milestone Scientific to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021

Milestone Scientific Inc told investors that its sales force expansion was paying off, as the company had won approval to supply its CompuFlo Epidural and CathCheck Verification System disposables across Florida's renowned Memorial Healthcare System network of hospitals. The company, which has developed instruments that provide painless and precise injections, also reported that the flagship institution - the Memorial Regional Hospital in Hollywood - had begun using its CompuFlo Epidural Instrument.

Milestone Scientific approved to supply its CompuFlo Epidural and CathCheck Verification System disposables across Florida's renowned Memorial Healthcare System

ROSELAND, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported that Memorial Regional Hospital in Hollywood, Fla., has begun the use of the CompuFlo Epidural Instrument. Memorial Regional Hospital is the flagship facility of the healthcare system and is one of the largest hospitals in Florida. Additionally, Milestone has received approval to eventually supply its CompuFlo Epidural and CathCheck Verification System disposables across Memorial Healthcare System network of hospitals, which also includes Joe DiMaggio Children's Hospital, Memorial Regional Hospital South, Memorial Hospital West, Memorial Hospital Miramar and Memorial Hospital Pembroke.

Milestone Scientific Approved as Vendor to Supply CompuFlo® Epidural/ CathCheck™ Verification System Across Florida's Memorial Heathcare System

Milestone Scientific Inc. (MLSS) CEO Arjan Haverhals on Q2 2021 Results - Earnings Call Transcript

Milestone Scientific, Inc. (MLSS) delivered earnings and revenue surprises of -100.00% and 7.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Milestone Scientific, Inc. (MLSS) Reports Q2 Loss, Tops Revenue Estimates

The stock price of Milestone Scientific Inc. (NYSEAMERICAN: MLSS) increased by over 3% pre-market. This is why it happened.

Milestone Scientific Shares Increase Over 3% Pre-Market: Why It Happened

Milestone Scientific Inc revealed that the re-opening of dentists in the US and globally helped the medtech group post a US$2.3 million increase in revenue to US$2.4 million in its second-quarter this year compared to US$168,000 for the year earlier period.  Gross profit for the three months to June 30, 2021, came in at US$1.4 million versus US$112,000 for the same quarter in 2020.

Milestone Scientific reports fourteen-fold increase in revenue in 2Q as dental business recovers

ROSELAND, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc . (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the second quarter ended June 30, 2021.

Milestone Scientific Reports Fourteen-Fold Increase in Revenue for Second Quarter of 2021

ROSELAND, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it will host a conference call at 11:00 A.M. Eastern Time on Monday, August 16, 2021 to discuss the Company's financial results for the second quarter ended June 30, 2021, as well as the Company's corporate progress and other developments.

News for Milestone Scientific Stock (MLSS)